Business Wire

Octapharma announces publication of data on fibryga® for the treatment of acquired fibrinogen deficiency in patients undergoing cardiac surgery

31.10.2019 15:04:00 EET | Business Wire | Press release

Share

Octapharma has announced the publication of new data demonstrating that the fibrinogen concentrate fibryga ® is an effective alternative to cryoprecipitate for patients with severe bleeding during cardiac surgery. The data were recently published in the Journal of the American Medical Association (JAMA).1

Excessive bleeding is a major concern during surgery, and excessive blood loss and/or clotting factor consumption can lead to deficiency in the coagulation factor fibrinogen. This acquired fibrinogen deficiency (AFD) can be treated with plasma-derived cryoprecipitate or with fibrinogen concentrates. Data on the use of fibrinogen concentrates in AFD have been limited until now. fibryga ® is a highly purified, dual pathogen-inactivated, lyophilised human fibrinogen concentrate for intravenous infusion, with rapid reconstitution for effective correction of fibrinogen deficiency.

The latest data on the use of fibrinogen concentrates in AFD are from the FIBRES trial, a multicentre, single-blind, randomised, comparator-controlled trial conducted in Canada to assess noninferiority of fibryga ® compared to cryoprecipitate in patients undergoing cardiac surgery. The trial enrolled 827 participants at 11 centres in Canada. In the publication, Dr Jeannie Callum and colleagues show that in these bleeding patients, the mean number of blood component transfusions needed for treatment, did not differ in patients receiving fibryga ® or cryoprecipitate in the 24 hours after cardiopulmonary bypass (16.3 vs 17.0, respectively; p < 0.001 for noninferiority). There were no differences in adverse events in the two groups. The data met the study’s prespecified noninferiority criterion and led to early termination of the trial. Full results are available online here.

Previous studies evaluating efficacy and safety of fibrinogen concentrates for the treatment of patients with severe bleeding have been limited by study size. The FIBRES trial represents the largest randomised, comparator-controlled clinical trial of fibrinogen concentrates in severe bleeding; the final analysis includes more patients than in all previous studies combined.

The data are of particular importance for regions where cryoprecipitate is the current standard treatment for AFD, and support the use of fibryga® for management of bleeding in patients undergoing cardiac surgery.

fibryga® has a fixed, labelled content of fibrinogen and is double pathogen-inactivated. It supplied as a lyophilized powder that can be stored at room temperature and reconstituted within minutes. The reconstituted product is stable at room temperature for 24 hours. Conversely, Cryoprecipitate, must be thawed before use and must be used within 4 hours of thawing. The amount of Fibrinogen in Cryoprecipitate can vary considerably from preparation to preparation. In addition, the pooling of plasma during the preparation of cryoprecipitate carries potential risk of infectious transmission.

Olaf Walter, Board Member at Octapharma said that “patients undergoing major surgery are in a very vulnerable situation and the availability of convenient treatments is critical. These latest results add to the growing portfolio of positive data for fibryga® and we are proud to be able to contribute to the rapid and effective treatment for people experiencing excessive bleeding”

fibryga® is approved to treat congenital fibrinogen deficiency in 15 countries in the European Union, as well as in the US and Canada. In Switzerland, fibryga® is approved to treat both congenital fibrinogen deficiency and AFD.

About fibryga®
fibryga® is a novel fibrinogen concentrate produced from pooled plasma providing fast reconstitution, dual pathogen safety, high level of purity, and functionality for the treatment of patients where fast and efficacious replacement of fibrinogen is needed. Indication of use may differ by country. Please consult local product information for country specific information or contact an Octapharma representative.

About Octapharma
The vision of Octapharma is: “Our passion drives us to provide new health solutions advancing human life”. Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood. Our company values are Ownership, Integrity, Leadership, Sustainability and Entrepreneurship.

In 2018, the Group achieved €1.8 billion in revenue, an operating income of €346 million and invested €240 million into R&D and in capital expenditures in order to ensure future prosperity. Octapharma employs 8,314 people worldwide to support the treatment of patients in 115 countries with products across three therapeutic areas:

  • Haematology (coagulation disorders)
  • Immunotherapy (immune disorders)
  • Critical care (bleeding management and functional volume replacement)

Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden.


1 Callum et al. Effect of fibrinogen concentrate vs cryoprecipitate on blood component transfusion after cardiac surgery - The FIBRES randomized clinical trial. JAMA 2019. doi:10.1001/jama.2019.17312. Published online October 21, 2019.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Octapharma AG
International Business Unit - Haematology
Olaf Walter
Olaf.Walter@octapharma.com

or

Oliver Hegener
oliver.hegener@octapharma.com
Tel: +41554512140

or

Ivana Spotakova
Communications Manager
Ivana.spotakova@octapharma.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

teamLab Biovortex Kyoto to Open ' Teahouse in a Sea of Light ' for Savoring Tea. On View from Friday, November 20. Artworks Including Tea in Spontaneous Order on View20.11.2026 08:00:00 EET | Press release

teamLab Biovortex Kyoto opens ‘Teahouse in a Sea of Light’ on Friday, November 20, 2026, where visitors can savor tea within the Sea of Solidified Light. Artworks exhibited in the teahouse, including Tea in Spontaneous Order, are now unveiled. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117922442/en/ Aged Coffee Tonic, Tea in Spontaneous Order, 2021- ©︎ teamLab *Shot in real space. No AI or CGI. *No Artificial Colors Teahouse in a Sea of Light A space for savoring tea within a sea of light. When a cup of tea is made, the artwork is born. The tea interacts with nearby tea and the sea of light, creating a time structure throughout the entire space of the artwork. Visitors drink part of this formed order itself. Coinciding with the opening of ‘Teahouse in a Sea of Light,’ Pocket Garden of Eternal Existence is newly unveiled at the museum's entrance gate. teamLab Biovortex Kyoto teamLab Biovortex Kyoto is teamLab's largest

CORRECTING and REPLACING Visa Expands Agentic Ready to Help Scale Trusted AI Commerce Globally19.11.2026 23:11:00 EET | Press release

This announcement replaces the release dated November 17, 2026 with the following version: J.P. Morgan Payments was added to the subhead and after the 11th paragraph. Multimedia was also updated. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117269823/en/ Visa Agentic Ready Acceptance Partners The updated release reads: VISA EXPANDS AGENTIC READY TO HELP SCALE TRUSTED AI COMMERCE GLOBALLY Adyen, Antom, Billtrust, Checkout.com, Fiserv, Global Payments, J.P. Morgan Payments, PayPal, Stripe along with over 140 initial participants join Agentic Ready program for acceptance ecosystem. Merchants, B2B suppliers, payment providers, acquirers and commerce platforms can now join the 175+ issuers already participating in Agentic Ready across 45 markets. Visa (NYSE: V), a world leader in digital payments, today announced the expansion of the Visa Agentic Ready program to the acceptance ecosystem. As a part of Visa Intelligent Commer

OCP Announces Date of Third Quarter and Nine-Month 2026 Earnings19.11.2026 18:30:00 EET | Press release

OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter and nine-month 2026 results on Monday, November 30, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 7:00 a.m. EDT, 12:00 p.m. Morocco and London time (GMT). OCP senior management will host a conference call to discuss third quarter and nine-month 2026 results at 8:00 a.m. EDT, 1:00 p.m. Morocco and London time (GMT) on Monday, November 30, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exclusive ac

ISACA Launches Updated COBIT 7 With Enhanced Assessment Model and Modern Digital Platform19.11.2026 17:24:00 EET | Press release

When AI can spark fears about humanity’s future and aging technology can bring air travel to a standstill, the cost of weak governance is impossible to ignore. To help enterprises strengthen the governance of their information and technology, ISACA has launched COBIT 7, an updated version of its globally recognized framework for information and technology (I&T) governance. Built for a rapidly changing digital world, the new COBIT 7 framework combines trusted guidance, an intuitive digital platform, customizable resources, and practical tools to help practitioners turn technology into measurable value, align decisions with strategy and confidently navigate emerging risks, including AI. COBIT 7 reinforces the framework’s longstanding role in helping businesses align their I&T operations with broader strategic goals, manage technology risks, and ensure regulatory compliance. “Over the last 30 years, COBIT has been a trusted framework for countless organizations, providing a holistic, stru

North Star Carbon Removal Project Selected by Government of Canada for Landmark Carbon Removal Procurement Program19.11.2026 17:04:00 EET | Press release

North Star, a planned large-scale carbon dioxide removal (CDR) project being developed by Meadow Lake Tribal Council (MLTC) and Svante Technologies Inc. (Svante), has been selected by the Government of Canada as a qualified supplier under the federal Request for Standing Offer (RFSO) for the Acquisition and Retirement of Credits from Carbon Dioxide Removal Projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118228180/en/ The proposed North Star bioenergy with carbon capture and storage project is being developed by the Meadow Lake Tribal Council (MLTC) and Svante. The project will generate durable carbon dioxide removal credits by capturing biogenic CO2 from the MLTC Bioenergy Center in Meadow Lake, SK, Canada, and storing it deep underground in a geological storage site. North Star was one of only three bioenergy with carbon capture and storage (BECCS) projects selected through the competitive process, following a r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye